McKesson Corporation (MCK) - Fiscal 2025 10-K Summary
Business Context and Reporting Period
Company: McKesson Corporation
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year ended March 31, 2025
Business Overview: A diversified healthcare services leader operating in four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The company distributes pharmaceuticals, medical supplies, and provides technology and clinical solutions to pharmacies, hospitals, and biopharma partners.
Key Financial Metrics
| Metric | Fiscal 2025 | Fiscal 2024 | Change |
|---|---|---|---|
| Revenues | $359.1 billion | $309.0 billion | +16% |
| Gross Profit | $13.3 billion | $12.8 billion | +4% |
| Gross Margin | 3.71% | 4.15% | -44 bps |
| Operating Income | $4.4 billion | $3.9 billion | +13% |
| Net Income (Attributable to MCK) | $3.3 billion | $3.0 billion | +10% |
| Diluted EPS | $25.72 | $22.39 | +15% |
| Operating Cash Flow | $6.1 billion | $4.3 billion | +41% |
| Total Debt | $5.7 billion | $5.6 billion | +0.4% |
| Cash & Equivalents | $5.7 billion | $4.6 billion | +24% |
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by the U.S. Pharmaceutical segment (+18%), fueled by higher volumes from retail national accounts and specialty pharmaceuticals. International segment revenue grew 4% despite unfavorable foreign currency fluctuations.
- Margin Compression: Gross margin decreased 44 basis points due to a $82 million LIFO charge (vs. a $157 million credit in 2024) and higher restructuring charges, partially offset by antitrust settlement gains.
- Significant Charges:
- Canadian Divestiture: Recorded a $667 million charge to remeasure the Canadian retail disposal group (Rexall/Well.ca) to fair value less costs to sell.
- Restructuring: Recorded $298 million in restructuring charges related to enterprise-wide efficiency initiatives.
- Opioid Litigation: Recorded a $108 million charge for estimated liabilities related to opioid claims.
- Significant Credits/Gains:
- Rite Aid Recovery: Recognized a $206 million credit reversing prior bad debt provisions following Rite Aid's emergence from bankruptcy.
- Antitrust Settlements: Received $444 million in antitrust legal settlement proceeds (recorded as a gain in Cost of Sales).
- Tax Benefit: Recognized a $258 million discrete tax benefit from intercompany intellectual property sales.
Guidance, Outlook, and Risks
- Strategic Separation: Announced intention to separate the Medical-Surgical Solutions segment into an independent company (May 2025).
- Divestitures: Completed the sale of Canadian retail businesses (Rexall/Well.ca) in December 2024. Continuing to evaluate exit alternatives for Norwegian retail operations.
- Acquisitions: Completed acquisition of PRISM Vision Holdings (ophthalmology services) and entered an agreement to acquire a controlling interest in Core Ventures (oncology services).
- Capital Allocation: Returned $3.5 billion to shareholders via $3.1 billion in share repurchases and $345 million in dividends. Quarterly dividend increased to $0.71 per share. Remaining repurchase authorization is approximately $7.5 billion.
- Key Risks:
- Opioid Litigation: Total estimated accrued liability is $6.4 billion. While settlements are ongoing, the company notes uncertainty regarding ultimate losses for non-settled matters.
- Customer Concentration: Top 10 customers represent 72% of revenue; CVS Health alone accounts for 24% of revenue and 23% of trade receivables.
- Regulatory Environment: Exposure to healthcare reform (Inflation Reduction Act), drug pricing negotiations, and supply chain security regulations (DSCSA).
Investor Verification Checklist
- Opioid Liability Exposure: Verify the $6.4 billion accrued liability and the potential for additional non-settled claims to impact future earnings.
- Medical-Surgical Spin-off: Assess the timeline and financial impact of the announced separation of the Medical-Surgical Solutions segment.
- Customer Concentration: Monitor the stability of the relationship with CVS Health (24% of revenue) and the impact of any contract renegotiations.
- Canadian Divestiture Impact: Confirm the final cash proceeds and the long-term effect of the $667 million remeasurement charge on the International segment's profitability.
- LIFO Volatility: Track pharmaceutical price inflation trends, as LIFO charges/credits significantly impact reported gross margins.